The curative effect and immune function influence of oxaliplatin combined with capecitabine in the treatment of patients with gastric cancer
-
摘要: 目的:探讨奥沙利铂联合卡培他滨治疗胃癌的临床疗效、安全性及对患者免疫功能的影响。方法:按随机数字表法将52例胃癌患者分为观察组和对照组,各26例。对照组应用奥沙利铂联合氟尿嘧啶与亚叶酸钙,观察组应用奥沙利铂联合卡培他滨,比较2组患者的临床疗效、T细胞亚群含量变化及不良反应发生率。结果:对照组和观察组的临床总有效率分别为61.54%和65.38%,差异无统计学意义(P0.05);化疗2 d及化疗后,2组患者的CD3+、CD4+含量均较化疗前降低(P0.05~P0.01),且2组患者化疗后CD3+、化疗2 d和化疗后CD4+含量差异均有统计学意义(P0.05~P0.01);而2组CD8+含量在化疗前后均无明显变化(P0.05),2组间差异无统计学意义(P0.05);观察组恶心呕吐、手足综合征及粒细胞下降的发生率均低于对照组(P0.05~P0.01)。结论:奥沙利铂联合卡培他滨治疗胃癌临床疗效肯定,安全性高,可保护患者的T细胞亚群,对机体免疫力影响较小,利于患者康复,值得临床推广。Abstract: ObjectiveTo investigate the clinical curative effects， safety and immune function influence of oxaliplatin combined with capecitabine in the treatment of patients with gastric cancer. Methods: Fifty-two patients with gastric cancer were randomly divided into treatment group and control group( 26 cases each group) .The control group were treated with oxaliplatin combined with 5-fluorouracil and calcium folinate.the treatment group were treated with oxaliplatin combined with capecitabine.The curative effects， levels of T cell subgroup and incidence of adverse reactions of two groups were compared.Results: The total effective rates of the control group and treatment group were 61.54% and 65.38%， the difference of which had no statistical significance( P 0.05) .Compared with before chemotherapy， the levels of CD3 + and CD4 + of two groups decreased after chemotherapy and 2 days in chemotherapy( P 0.05 to P 0.01) .The differences of the levels of CD3 + after chemotherapy and CD4 + after chemotherapy and 2 days in chemotherapy in two groups had statistical significance( P 0.05 to P 0.01) .The levels of CD8 + in two groups did not obviously change before and after chemotherapy， the difference of which had no statistical significance ( P 0.05) .The incidence of nausea and vomiting，hand-foot syndrome and granulocyte declining in treatment group were lower than those in control group( P 0.05 to P 0.01) . Conclusions:Oxaliplatin combined with capecitabine in the treatment of patients with gastric cancer is good effects，high safety and little influence on immunity，which can protect the T cell subgroup， conducive to the rehabilitation of patients，be worthy of being widely applied in clinic.
-
Keywords:
- gastric neoplasms /
- oxaliplatin /
- capecitabine /
- immune function
-
-
[1] [2] 顾军，王梅，李咏梅，等. XELOX 方案治疗进展期胃癌的临床观察[J]. 临床肿瘤学杂志，2 011，16( 9) : 809 － 813. [1] 华萍. XELOX 化疗方案对胃癌患者免疫功能与治疗疗效的影响[J]. 吉林医学， 2012，33( 26) : 5687. [2] [3] 周俭，胡文军，孙翠玲，等. 紫杉醇联合亚叶酸钙和5-氟尿嘧啶治疗晚期胃癌临床观察[J]. 蚌埠医学院学报，2012，37 ( 7) :806 － 807. [3] [4] 赵文英，陈冬云，齐全.伊立替康或奥沙利铂联合卡培他滨治疗晚期胃癌的疗效比较[J]. 中华肿瘤杂志，2011，33 ( 4 ) :295 － 298. [4] [5] Adams rA，Meade AM，Seymour MT，et al. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MrC COIN trial[J]. Lancet Oncol，2011，12( 7) : 642 － 653.
[5] [6] Okines AF，Ashley SE，Cunningham D，et al. Epirubicin，oxaliplatin，and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter，randomized，phase Ⅱ/Ⅲ rEAL-3 trial[J]. J Clin Oncol， 2010， 28( 25) : 3945 － 3950.
[6] [7] 戴闯. 80 例奥沙利铂联合卡培他滨用于晚期肝内胆管癌的临床疗效分析[J]. 海峡药学， 2012，24( 8) : 138 － 140. [7] [8] 王磊，胡冰，季楚舒，等. XELOX 与FLO 方案治疗晚期胃癌的近期疗效及毒副反应比较[J]. 安徽医药， 2011， 15( 3) : 329 － 330. [8] [9] 张红宇，吴昌，吴骏，等. EOF 与XELOX 方案治疗晚期胃癌的疗效与不良反应比较[J]. 蚌埠医学院学报，2011，36 ( 12) :1325 － 1327. [9] [10] 王爱英，张毛讲. 卡培他滨联合奥沙利铂治疗晚期胃癌的临床观察[J]. 中国医药导报，2012，9( 6) : 58 － 59. [10] [11] 胡章华，毛绍蓉. XELOX 化疗方案用于老年晚期胃癌患者治疗的临床观察[J]. 重庆医学，2 013，42( 2) : 156 － 159. [11] [12] 樊翠珍，初玉平，戴红. 卡培他滨联合奥沙利铂与替吉奥联合奥沙利铂治疗进展期胃癌的对比研究[J]. 临床肿瘤学杂志，2011， 16( 8) : 725 － 727. [12] [13] 陈冬生，张春晓，田安庆，等. 奥沙利铂联合卡培他滨治疗晚期胃癌的临床观察[J]. 实用癌症杂志，2010，25 ( 2) : 167 －168. [13] [14] 张洁，肖雅，陆明，等. 卡培他滨单药或联合方案治疗晚期胃癌的临床研究[J]. 中华肿瘤杂志，2009，31( 4) : 312 － 315.
计量
- 文章访问数: 3211
- HTML全文浏览量: 275
- PDF下载量: 108
下载:
